Patents by Inventor James Joseph Onuffer
James Joseph Onuffer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250236889Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARS, recognition domains, and/or pH-modulating agents.Type: ApplicationFiled: April 8, 2025Publication date: July 24, 2025Applicant: Exuma Biotech Corp.Inventors: Gregory Ian FROST, James Joseph ONUFFER, JR., Ghiabe H. GUIBINGA, Farzad HAERIZADEH, Anirban KUNDU
-
Patent number: 12325728Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.Type: GrantFiled: April 12, 2022Date of Patent: June 10, 2025Assignee: Exuma Biotech Corp.Inventors: Gregory Ian Frost, James Joseph Onuffer, Jr., Ghiabe H. Guibinga, Farzad Haerizadeh, Frederic Vigant, Anirban Kundu
-
Patent number: 12258574Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.Type: GrantFiled: May 23, 2023Date of Patent: March 25, 2025Assignee: Exuma Biotech Corp.Inventors: Gregory Ian Frost, James Joseph Onuffer, Jr., Ghiabe H. Guibinga, Farzad Haerizadeh, Anirban Kundu
-
Publication number: 20250026840Abstract: The present disclosure provides chimeric antigen receptors that bind to Axl and Ror2, and conditionally active chimeric antigen receptors (CARs) that recognize Axl and Ror2. Furthermore, provided herein are nucleic acids encoding these CARs and methods of making and using the CARs, including methods of treating cancer, especially cancers that express Axl and/or Ror2, such as renal cell carcinoma. The present disclosure provides cells genetically modified to produce the CARs.Type: ApplicationFiled: October 4, 2024Publication date: January 23, 2025Applicants: Exuma Biotech Corp., BioAtla, Inc.Inventors: Gregory Ian FROST, James Joseph ONUFFER, Jr., Jay M. SHORT, Gerhard FREY, Hwai Wen CHANG
-
Patent number: 12187801Abstract: The present disclosure provides chimeric antigen receptors that bind to Axl and Ror2, and conditionally active chimeric antigen receptors (CARs) that recognize Axl and Ror2. Furthermore, provided herein are nucleic acids encoding these CARs and methods of making and using the CARs, including methods of treating cancer, especially cancers that express Axl and/or Ror2, such as renal cell carcinoma. The present disclosure provides cells genetically modified to produce the CARs.Type: GrantFiled: January 17, 2018Date of Patent: January 7, 2025Assignees: Exuma Biotech Corp., BioAtla. Inc.Inventors: Gregory Ian Frost, James Joseph Onuffer, Jr., Jay M. Short, Gerhard Frey, Hwai Wen Chang
-
Publication number: 20230392139Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.Type: ApplicationFiled: June 14, 2023Publication date: December 7, 2023Applicant: Exuma Biotech Corp.Inventors: Gregory Ian FROST, James Joseph ONUFFER, Jr., Ghiabe H. GUIBINGA, Farzad HAERIZADEH
-
Publication number: 20230340536Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.Type: ApplicationFiled: May 23, 2023Publication date: October 26, 2023Applicant: Exuma Biotech Corp.Inventors: Gregory Ian FROST, James Joseph ONUFFER, Jr., Ghiabe H. Guibinga, Farzad HAERIZADEH, Anirban KUNDU
-
Publication number: 20230257776Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.Type: ApplicationFiled: April 17, 2023Publication date: August 17, 2023Applicant: Exuma Biotech Corp.Inventors: Gregory Ian FROST, James Joseph ONUFFER, Jr., Ghiabe H. Guibinga, Farzad HAERIZADEH, Anirban KUNDU
-
Publication number: 20230072955Abstract: The present disclosure provides chimeric antigen receptors (CARs), and nucleic acids comprising nucleotide sequences encoding the CARs, that bind to HER2, and conditionally active biologic (CAB) CARs that bind to HER2. The present disclosure provides cells genetically modified to produce the CARs, delivery suspensions comprising these genetically modified cells, and methods for making such cells. The CARs of the present disclosure can be used in various methods, which are also provided, including methods for activating immune cells under certain conditions, and methods for performing adoptive cell therapy such as CAR therapy, for example CAR therapy against cancer.Type: ApplicationFiled: January 23, 2021Publication date: March 9, 2023Applicants: Exuma Biotech Corp, BioAtla, Inc.Inventors: Gregory Ian Frost, James Joseph Onuffer, JR., Anirban Kundu, Jay M. Short, Gerhard Frey, Hwai Wen Chang
-
Publication number: 20220340927Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells. In some embodiments, the methods include reaction mixtures, and resulting cell formulations, that are created using whole blood, or a component thereof that is not a PBMC, and additionally comprise T cells and recombinant retroviral particles having polynucleotides that encode a CAR. In some embodiments, modified lymphocytes are reintroduced into a subject subcutaneously. In some embodiments, polynucleotides that provide T cells the ability to regulate cell survival and proliferation in response to binding to a CAR, are provided.Type: ApplicationFiled: August 31, 2020Publication date: October 27, 2022Applicant: Exuma Biotech Corp.Inventors: Gregory Ian Frost, James Joseph Onuffer, Farzad Haerizadeh, Frederic Vigant, Anirban Kundu
-
Publication number: 20220306698Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.Type: ApplicationFiled: April 12, 2022Publication date: September 29, 2022Applicant: Exuma Biotech Corp.Inventors: Gregory Ian Frost, James Joseph Onuffer, Jr., Ghiabe H. Guibinga, Farzad Haerizadeh, Frederic Vigant, Anirban Kundu
-
Patent number: 11325948Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.Type: GrantFiled: December 2, 2020Date of Patent: May 10, 2022Assignee: Exuma Biotech Corp.Inventors: Gregory Ian Frost, James Joseph Onuffer, Jr., Ghiabe H. Guibinga, Farzad Haerizadeh, Frederic Vigant, Anirban Kundu
-
Publication number: 20210403952Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.Type: ApplicationFiled: September 6, 2021Publication date: December 30, 2021Applicant: EXUMA BIOTECH CORP.Inventors: Gregory Ian FROST, James Joseph ONUFFER, Ghiabe H. GUIBINGA, Farzad HAERIZADEH, Anirban KUNDU
-
Publication number: 20210317408Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.Type: ApplicationFiled: September 2, 2019Publication date: October 14, 2021Applicant: Exuma Biotech Corp.Inventors: Gregory Ian Frost, James Joseph Onuffer, Farzad Haerizadeh, Frederic Vigant, Anirban Kundu
-
Patent number: 11111505Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.Type: GrantFiled: July 8, 2017Date of Patent: September 7, 2021Assignee: EXUMA BIOTECH, CORP.Inventors: Gregory Ian Frost, James Joseph Onuffer, Ghiabe H. Guibinga, Farzad Haerizadeh, Anirban Kundu
-
Publication number: 20210107949Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.Type: ApplicationFiled: December 2, 2020Publication date: April 15, 2021Applicant: Exuma Biotech Corp.Inventors: Gregory Ian Frost, James Joseph Onuffer, Ghiabe H. Guibinga, Farzad Haerizadeh, Frederic Vigant, Anirban Kundu
-
Publication number: 20200397821Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.Type: ApplicationFiled: March 3, 2018Publication date: December 24, 2020Applicant: EXUMA BIOTECH CORPInventors: Gregory Ian FROST, James Joseph ONUFFER, Ghiabe H. GUIBINGA, Farzad HAERIZADEH
-
Publication number: 20200255864Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes and related methods that include genetically modifying T cells and/or NK cells. The methods use replication incompetent recombinant retroviral particles that comprise a pseudotyping element on their surface and optionally a membrane-bound T cell activation element, such as an anti-CD3, and encode one or more engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR). The methods can include contacting PBMCs with replication incompetent recombinant retroviral particles for various exemplary time periods, such as less than 24 hours or in some illustrative embodiments less than 15 minutes. In some aspects, the present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in whole blood or a component thereof.Type: ApplicationFiled: March 18, 2020Publication date: August 13, 2020Applicant: Exuma Biotech Corp.Inventors: Gregory Ian FROST, James Joseph ONUFFER, Farzad HAERIZADEH, Frederic VIGANT, Anirban KUNDU
-
Patent number: 10596274Abstract: The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells without prior ex vivo stimulation. The methods typically include engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted CAR. Additional elements of such engineered signaling polypeptides are provided herein, as well as vectors, such as retroviral vectors, packaging cell lines and methods of making the same. Furthermore, recombinant retroviruses and methods of making the same are provided. Numerous controls are provided, including riboswitches that are controlled, for example in vivo, by nucleoside analogues.Type: GrantFiled: March 19, 2017Date of Patent: March 24, 2020Assignee: Exuma Biotech Corp.Inventors: Gregory Ian Frost, James Joseph Onuffer, Ghiabe H. Guibinga
-
Publication number: 20190367876Abstract: The present disclosure provides methods for genetically modifying and expanding immune cells ex vivo, especially for use in cell-based adoptive immunotherapy. As such, method embodiments are provided for transducing immune cells (e.g. T cells and/or NK cells) that include a step of activating the cells and genetically modifying the activated cells, for example by transducing the cells with recombinant retroviral particles, such as lentiviral particles. Genetically modified cells produced by these methods are also provided. Such methods are typically performed within a closed system, and in illustrative embodiments within a single chamber of a closed system. The methods typically include expanding the genetically modified immune cells in cell expansion media within the closed system, in illustrative embodiments within the single chamber of the closed system. As such, provided herein in illustrative embodiments, are fed-batch, single-reactor method systems.Type: ApplicationFiled: January 17, 2018Publication date: December 5, 2019Applicant: F1 ONCOLOGY, INC.Inventors: Gregory Ian FROST, James Joseph ONUFFER